Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.70 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.70 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.70 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoleucine SCHEMBL112017 | 0.85 | DPP4 (0.43) | DPP4DPP7DPP8DPP9 | |
| Isoleucine SCHEMBL480974 | 0.85 | DPP4 (0.43) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL356202 | 0.84 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL12291433 | 0.84 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL353709 | 0.84 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL392505 | 0.84 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL846295 | 0.84 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5708931 | 0.83 | DPP4 (0.97) | DPP4DPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5708932 | 0.83 | DPP4 (0.97) | DPP4DPP7DPP8DPP9 | |
| Fumaric Acid SCHEMBL21638348 | 0.79 | DPP4 (0.84) | DPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8030270-B2 | Methods for identifying GLP-1 secretagogues | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8022034-B2 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8003597-B2 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2322150-A2 | Method of identifying GLP-1 secretagogues | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322152-A1 | Method of preparing a composition comprising a GPR119 agonist | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322157-A1 | Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322151-A2 | Sustained release formulation comprising a GPR119 agonist and a DPP-IV inhibitor | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322156-A1 | Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2004157-B1 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | ARENA PHARM INC (US) | 2011-01-12 | — | — | EP | disclosed |